Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5(+) diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report

CONCLUSIONS: These findings suggest that toripalimab may be a new therapeutic option for central nervous system recurrence in refractory CD5+ DLBCL with MYD88 and CD79B comutation. Further clinical trials are warranted to confirm these results.PMID:38482415 | PMC:PMC10928622 | DOI:10.21037/tcr-23-1638

Source: Cell Research - March 14, 2024 Category: Cytology Authors: Xi Chen Zhihan Zhang Junbao Zhang Qiuxiao Yu Junjing Qiu Yajie Xiao Binbin Chen Ping Xu Source Type: research